DOCSLIB.ORG

Advances in Adult and Non-Embryonic Stem Cell Research

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advances in Adult and Non-Embryonic Stem Cell Research S. HRG. 108–949 ADVANCES IN ADULT AND NON-EMBRYONIC STEM CELL RESEARCH HEARING BEFORE THE SUBCOMMITTEE ON SCIENCE, TECHNOLOGY, AND SPACE OF THE COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION UNITED STATES SENATE ONE HUNDRED EIGHTH CONGRESS FIRST SESSION JUNE 12, 2003 Printed for the use of the Committee on Commerce, Science, and Transportation ( U.S. GOVERNMENT PRINTING OFFICE 80–903 PDF WASHINGTON : 2013 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 VerDate Nov 24 2008 06:41 May 20, 2013 Jkt 075679 PO 00000 Frm 00001 Fmt 5011 Sfmt 5011 S:\GPO\DOCS\80903.TXT JACKIE SENATE COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION ONE HUNDRED EIGHTH CONGRESS FIRST SESSION JOHN MCCAIN, Arizona, Chairman TED STEVENS, Alaska ERNEST F. HOLLINGS, South Carolina, CONRAD BURNS, Montana Ranking TRENT LOTT, Mississippi DANIEL K. INOUYE, Hawaii KAY BAILEY HUTCHISON, Texas JOHN D. ROCKEFELLER IV, West Virginia OLYMPIA J. SNOWE, Maine JOHN F. KERRY, Massachusetts SAM BROWNBACK, Kansas JOHN B. BREAUX, Louisiana GORDON H. SMITH, Oregon BYRON L. DORGAN, North Dakota PETER G. FITZGERALD, Illinois RON WYDEN, Oregon JOHN ENSIGN, Nevada BARBARA BOXER, California GEORGE ALLEN, Virginia BILL NELSON, Florida JOHN E. SUNUNU, New Hampshire MARIA CANTWELL, Washington FRANK R. LAUTENBERG, New Jersey JEANNE BUMPUS, Republican Staff Director and General Counsel ROBERT W. CHAMBERLIN, Republican Chief Counsel KEVIN D. KAYES, Democratic Staff Director and Chief Counsel GREGG ELIAS, Democratic General Counsel SUBCOMMITTEE ON SCIENCE, TECHNOLOGY, AND SPACE SAM BROWNBACK, Kansas, Chairman TED STEVENS, Alaska JOHN B. BREAUX, Louisiana, Ranking CONRAD BURNS, Montana JOHN D. ROCKEFELLER IV, West Virginia TRENT LOTT, Mississippi JOHN F. KERRY, Massachusetts KAY BAILEY HUTCHISON, Texas BYRON L. DORGAN, North Dakota JOHN ENSIGN, Nevada RON WYDEN, Oregon GEORGE ALLEN, Virginia BILL NELSON, Florida JOHN E. SUNUNU, New Hampshire FRANK R. LAUTENBERG, New Jersey (II) VerDate Nov 24 2008 06:41 May 20, 2013 Jkt 075679 PO 00000 Frm 00002 Fmt 5904 Sfmt 5904 S:\GPO\DOCS\80903.TXT JACKIE C O N T E N T S Page Hearing held on June 12, 2003 ............................................................................... 1 Statement of Senator Brownback ........................................................................... 1 Prepared statement .......................................................................................... 2 WITNESSES Barsh, Steven L., Merion Station, Pennsylvania .................................................. 40 Prepared statement .......................................................................................... 42 Hess, David C., Professor and Chairman, Department of Neurology, Medical College of Georgia ................................................................................................ 3 Prepared statement .......................................................................................... 6 Kurtzberg, M.D., Joanne, Director, Pediatric Stem Cell Transplant Program, Duke University Medical Center ........................................................................ 11 Prepared statement .......................................................................................... 15 McDonald, M.D., Ph.D., John, on behalf of the Coalition for the Advancement of Medical Research ............................................................................................. 23 Prepared statement .......................................................................................... 25 Peduzzi-Nelson, Ph.D., Jean D., Department of Physiological Optics, Univer- sity of Alabama at Birmingham .......................................................................... 26 Prepared statement .......................................................................................... 28 Penn, Keone, Snellville, Georgia ............................................................................ 47 Prepared statement .......................................................................................... 48 Rubinstein, M.D., Pablo, Director of Placental Blood Program, New York Blood Center ......................................................................................................... 9 Prepared statement .......................................................................................... 15 Sprague, Stephen R., Staten Island, New York .................................................... 44 Prepared statement .......................................................................................... 45 APPENDIX Testimony of the American Academy of Physician Assistants ............................ 55 (III) VerDate Nov 24 2008 06:41 May 20, 2013 Jkt 075679 PO 00000 Frm 00003 Fmt 5904 Sfmt 5904 S:\GPO\DOCS\80903.TXT JACKIE VerDate Nov 24 2008 06:41 May 20, 2013 Jkt 075679 PO 00000 Frm 00004 Fmt 5904 Sfmt 5904 S:\GPO\DOCS\80903.TXT JACKIE ADVANCES IN ADULT AND NON-EMBRYONIC STEM CELL RESEARCH THURSDAY, JUNE 12, 2003, U.S. SENATE, SUBCOMMITTEE ON SCIENCE, TECHNOLOGY, AND SPACE, COMMITTEE ON COMMERCE, SCIENCE, AND TRANSPORTATION, Washington, DC. The Subcommittee met, pursuant to notice, at 2:46 p.m. in room SR–253, Russell Senate Office Building, Hon. Sam Brownback, Chairman of the Subcommittee, presiding. OPENING STATEMENT OF HON. SAM BROWNBACK, U.S. SENATOR FROM KANSAS Senator BROWNBACK. The hearing will come to order. I want to thank everybody for being here today, particularly the witnesses that traveled some distance. We have a couple of really special ones—not that all of you aren’t special, but I think you’re going to find these just particularly heartening stories of incredible things that have taken place. Today, we’ll be conducting a hearing on some of the exciting new advances being made in the fields of adult and non-embryonic stem cell research. As I’m sure many of you know, the field of regenera- tive medicine offers great hope to those suffering from this disease. Much of the research that is providing new hope to those who are currently suffering is moving along at a fast pace and is doing so without questionable or morally controversial techniques. At this hearing, we will examine some of these advances. This hearing is not about human cloning or destructive human embry- onic stem cell research. Rather, it is about some of the other impor- tant scientific discoveries that are being made using noncontrover- sial techniques that rely on adult or non-embryonic stem cells. And these are some processes that only a year-and-a-half ago, we’ll re- call, were being called ‘‘junk science.’’ And yet you’re going to hear today from people that have been cured. So there’s been amazing work, fabulous work, that has really resulted in people’s lives being changed. In particular today, we will hear from cord-blood stem cell re- searchers, as well as others, who are working hard in the field of regenerative medicine to find the cures to the diseases that plague humanity. At this hearing, we will discuss not only some of the re- search that is being conducted, but also some of the treatments that are currently being offered. And we will hear from some of the patients who are benefiting from this important life-saving re- search. The stories that we will hear from some of the patients will (1) VerDate Nov 24 2008 06:41 May 20, 2013 Jkt 075679 PO 00000 Frm 00005 Fmt 6633 Sfmt 6633 S:\GPO\DOCS\80903.TXT JACKIE 2 truly be astounding. They are miraculous. We all agree on the need to work hard toward a cure for the diseases that plague humanity, and we’re going to be listening to some of that success here today. Now, rather than discussing this, I’d like to take advantage of the panels that we have here today to testify. I want to turn to our first panel of people to testify. And they are Dr. David Hess, M.D., Chairman and Professor, Department of Neurology, Medical Col- lege of Georgia, in Augusta, Georgia; Dr. Joanne Kurtzberg, M.D., Director of the Pediatric Stem Cell Transplant Program at Duke University Medical Center, in Durham, North Carolina—being a KU grad, I’m familiar with Duke—— [Laughter.] Senator BROWNBACK.—and a very good school, other than in bas- ketball—— [Laughter.] Senator BROWNBACK.—Dr. John W. McDonald, M.D., Ph.D., Washington University School of Medicine, Department of Neu- rology, in St. Louis, Missouri; Dr. Jean Peduzzi-Nelson, Ph.D., Uni- versity of Alabama at Birmingham; and Dr. Pablo Rubinstein, M.D., Director of Placental Blood Program, New York Blood Cen- ter, New York, New York. I’m delighted to have such a distinguished panel here with us today to testify. I look forward to your testimony. If you would, we will run the clock on 7 minutes. We will take your full testimony into the record. I think it’s always best for people to summarize somewhat in putting it forward, so it can save time, as well, for questions afterwards. We do have an active floor running today. We may have to have recesses periodically, for me to go over and vote. Other members will probably be joining us, as well, so there may be some people stepping in. [The prepared statement of Senator Brownback follows:] PREPARED STATEMENT OF HON. SAM BROWNBACK, U.S. SENATOR FROM KANSAS Thank you for coming to our hearing today. Today, we will be conducting a hearing on some of the exciting new advances being made in the fields of adult and non-embryonic stem cell
Load more

Recommended publications
  • Characterization of Embryonic Stem Cell-Differentiated Cells As Mesenchymal Stem Cells
    The University of Southern Mississippi The Aquila Digital Community Honors Theses Honors College Fall 12-2015 Characterization of Embryonic Stem Cell-Differentiated Cells as Mesenchymal Stem Cells Rachael N. Kuehn University of Southern Mississippi Follow this and additional works at: https://aquila.usm.edu/honors_theses Part of the Cell Biology Commons Recommended Citation Kuehn, Rachael N., "Characterization of Embryonic Stem Cell-Differentiated Cells as Mesenchymal Stem Cells" (2015). Honors Theses. 349. https://aquila.usm.edu/honors_theses/349 This Honors College Thesis is brought to you for free and open access by the Honors College at The Aquila Digital Community. It has been accepted for inclusion in Honors Theses by an authorized administrator of The Aquila Digital Community. For more information, please contact [email protected]. The University of Southern Mississippi Characterization of Embryonic Stem Cell-Differentiated Cells as Mesenchymal Stem Cells by Rachael Nicole Kuehn A Thesis Submitted to the Honors College of The University of Southern Mississippi in Partial Fulfillment of the Requirements for the Degree of Bachelor of Science in the Department of Biological Sciences December 2015 ii Approved by ______________________________ Yanlin Guo, Ph.D., Thesis Adviser Professor of Biological Sciences ______________________________ Shiao Y. Wang, Ph.D., Chair Department of Biological Sciences ______________________________ Ellen Weinauer, Ph.D., Dean Honors College iii ABSTRACT Embryonic stem cells (ESCs), due to their ability to differentiate into different cell types while still maintaining a high proliferation capacity, have been considered as a potential cell source in regenerative medicine. However, current ESC differentiation methods are low yielding and create heterogeneous cell populations.
    [Show full text]
  • Boosting the Cellular Potency of Embryonic Stem Cells by Spliceosome Targeting ✉ Wilfried A
    Signal Transduction and Targeted Therapy www.nature.com/sigtrans RESEARCH HIGHLIGHT OPEN Boosting the cellular potency of embryonic stem cells by spliceosome targeting ✉ Wilfried A. Kues1 Signal Transduction and Targeted Therapy (2021) 6:324; https://doi.org/10.1038/s41392-021-00743-9 In recent work published in Cell, Shen et al.1 identified transfected ES cells with short interfering RNAs against different spliceosome inhibition in embryonic stem (ES) cells as a key spliceosome transcripts (the spliceosome consisted of 5 core and mechanism for the transition from pluri- to totipotency. Spliceo- several cofactor subunits, here 14 transcripts were targeted), some inhibition, achieved by RNA interference or the chemical respectively. Transient repression of 10 of the 14 splicing factors inhibitor pladienolide B, may gain widespread relevance to the resulted in ES cells, which maintained the typical colony culture of totipotent ES cells, in vitro differentiation of extra- morphology, however, pluripotent marker genes—Oct4 (Pou5f1), embryonal tissue and organoids, translation to the maintenance of Nanog, Sox2, Zfp42 and others—became down-regulated, at the pluripotent cells of other mammal species, including humans, and same time marker genes of totipotency—particularly Zscan4s and a better molecular understanding of cellular potency in stem cells MERVL—were up-regulated. Zscan4s (Zink finger and SCAN and cancer. domain containing 4) is a transcription factor and MERVL (murine The first successful isolation and maintenance of ES derived endogenous retrovirus L) an endogenous retrovirus with a usually fi 1234567890();,: from the inner cell mass (ICM) of murine blastocyst stages was restricted expression to 2-cell embryos. These results were veri ed described in 1981,2 and since then acted as game changer for by supplementing the culture medium with pladienolide B, a genetic studies in this mammalian model organism.
    [Show full text]
  • A Concise Review on the Classification and Nomenclature of Stem Cells Kök Hücrelerinin S›N›Fland›R›Lmas› Ve Isimlendirilmesine Iliflkin K›Sa Bir Derleme
    Review 57 A concise review on the classification and nomenclature of stem cells Kök hücrelerinin s›n›fland›r›lmas› ve isimlendirilmesine iliflkin k›sa bir derleme Alp Can Ankara University Medical School, Department of Histology and Embryology, Ankara, Turkey Abstract Stem cell biology and regenerative medicine is a relatively young field. However, in recent years there has been a tremen- dous interest in stem cells possibly due to their therapeutic potential in disease states. As a classical definition, a stem cell is an undifferentiated cell that can produce daughter cells that can either remain a stem cell in a process called self-renew- al, or commit to a specific cell type via the initiation of a differentiation pathway leading to the production of mature progeny cells. Despite this acknowledged definition, the classification of stem cells has been a perplexing notion that may often raise misconception even among stem cell biologists. Therefore, the aim of this brief review is to give a conceptual approach to classifying the stem cells beginning from the early morula stage totipotent embryonic stem cells to the unipotent tissue-resident adult stem cells, also called tissue-specific stem cells. (Turk J Hematol 2008; 25: 57-9) Key words: Stem cells, embryonic stem cells, tissue-specific stem cells, classification, progeny. Özet Kök hücresi biyolojisi ve onar›msal t›p görece yeni alanlard›r. Buna karfl›n, son y›llarda çeflitli hastal›klarda tedavi amac›yla kullan›labilme potansiyelleri nedeniyle kök hücrelerine ola¤anüstü bir ilgi art›fl› vard›r. Klasik tan›m›yla kök hücresi, kendini yenileme ad› verilen mekanizmayla farkl›laflmadan kendini ço¤altan veya bir dizi farkl›laflma aflamas›ndan geçerek olgun hücrelere dönüflebilen hücrelerdir.
    [Show full text]
  • Ethical Challenges in Organoid Use
    Article Ethical Challenges in Organoid Use Vasiliki Mollaki Hellenic National Bioethics Commission, PC 10674 Athens, Greece; [email protected] Abstract: Organoids hold great promises for numerous applications in biomedicine and biotech- nology. Despite its potential in science, organoid technology poses complex ethical challenges that may hinder any future benefits for patients and society. This study aims to analyze the multifaceted ethical issues raised by organoids and recommend measures that must be taken at various levels to ensure the ethical use and application of this technology. Organoid technology raises several serious ethics issues related to the source of stem cells for organoid creation, informed consent and privacy of cell donors, the moral and legal status of organoids, the potential acquisition of human “characteristics or qualities”, use of gene editing, creation of chimeras, organoid transplantation, commercialization and patentability, issues of equity in the resulting treatments, potential misuse and dual use issues and long-term storage in biobanks. Existing guidelines and regulatory frameworks that are applicable to organoids are also discussed. It is concluded that despite the serious ethical challenges posed by organoid use and biobanking, we have a moral obligation to support organoid research and ensure that we do not lose any of the potential benefits that organoids offer. In this direction, a four-step approach is recommended, which includes existing regulations and guidelines, special regulatory provisions that may be needed, public engagement and continuous monitoring of the rapid advancements in the field. This approach may help maximize the biomedical and social benefits of organoid technology and contribute to future governance models in organoid technology.
    [Show full text]
  • Electrophysiology Read-Out Tools for Brain-On-Chip Biotechnology
    micromachines Review Electrophysiology Read-Out Tools for Brain-on-Chip Biotechnology Csaba Forro 1,2,†, Davide Caron 3,† , Gian Nicola Angotzi 4,†, Vincenzo Gallo 3, Luca Berdondini 4 , Francesca Santoro 1 , Gemma Palazzolo 3,* and Gabriella Panuccio 3,* 1 Tissue Electronics, Fondazione Istituto Italiano di Tecnologia, Largo Barsanti e Matteucci, 53-80125 Naples, Italy; [email protected] (C.F.); [email protected] (F.S.) 2 Department of Chemistry, Stanford University, Stanford, CA 94305, USA 3 Enhanced Regenerative Medicine, Fondazione Istituto Italiano di Tecnologia, Via Morego, 30-16163 Genova, Italy; [email protected] (D.C.); [email protected] (V.G.) 4 Microtechnology for Neuroelectronics, Fondazione Istituto Italiano di Tecnologia, Via Morego, 30-16163 Genova, Italy; [email protected] (G.N.A.); [email protected] (L.B.) * Correspondence: [email protected] (G.P.); [email protected] (G.P.); Tel.: +39-010-2896-884 (G.P.); +39-010-2896-493 (G.P.) † These authors contributed equally to this paper. Abstract: Brain-on-Chip (BoC) biotechnology is emerging as a promising tool for biomedical and pharmaceutical research applied to the neurosciences. At the convergence between lab-on-chip and cell biology, BoC couples in vitro three-dimensional brain-like systems to an engineered microfluidics platform designed to provide an in vivo-like extrinsic microenvironment with the aim of replicating tissue- or organ-level physiological functions. BoC therefore offers the advantage of an in vitro repro- duction of brain structures that is more faithful to the native correlate than what is obtained with conventional cell culture techniques.
    [Show full text]
  • Cellular Biomems
    Chapter 11. Cellular BioMEMS Cellular BioMEMS Academic and Research Staff Professor Joel Voldman Postdoctoral Associates Alison Skelley, Katarina Blagović, Wei Mong Tsang Graduate Students Salil Desai, Lily Kim, Joseph Kovac, Hsu-Yi Lee , Nick Mittal, Katya Puchala, Laralynne Przybyla, Adam Rosenthal, Somponnat Sampattavanich, Brian Taff, Michael Vahey Undergraduate Students Stephanie Cheng, Asiri Ediriwickrema, Stephanie Flavin, Shanette Go, Alice Macdonald, Brianna Petrone, Hari Singhal Technical and Support Staff Chadwick Collins Laboratory for Cellular BioMEMS – Research Themes Our group performs research on BioMEMS, applying microfabrication technology to illuminate biological systems, especially at the cellular level. Specifically, we develop technologies that are used to manipulate cells or make measurements from them. Our research builds upon various disciplines: electrical engineering, microfabrication, bioengineering, surface science, fluid mechanics, mass transport, etc. We take a quantitative approach to designing our technology, using both analytical and numerical modeling to gain fundamental understanding of the technologies that we create. We then take our designs through microfabrication to packaging and testing and to biological assay. Our applications have a strong emphasis on stem cell biology and cell screening. 1. Single-cell manipulation platforms for cell cytometry Sponsors NIH NCRR NSF Graduate Research Fellowship NDSEG Graduate Research Fellowship Singapore-MIT Alliance Project Staff Salil Desai, Nick Mittal, Joseph Kovac, Brian Taff, Brianna Petrone, Hari Singhal Figure 1: A generic single-cell manipulation platform. In such devices individual cells are organized in unique Overview addressable locations for a host of different analyses. As an example format, we show a two-dimensional array of traps. The goal of this research is In functional form, we aim to localize distinct cell populations the development of a series to various portions of the device surface.
    [Show full text]
  • An Introduction to Stem Cell Biology
    An Introduction to Stem Cell Biology Michael L. Shelanski, MD,PhD Professor of Pathology and Cell Biology Columbia University Figures adapted from ISSCR. Presentations of Drs. Martin Pera (Monash University), Dr.Susan Kadereit, Children’s Hospital, Boston and Dr. Catherine Verfaillie, University of Minnesota Science 1999, 283: 534-537 PNAS 1999, 96: 14482-14486 Turning Blood into Brain: Cells Bearing Neuronal Antigens Generated in Vitro from Bone Marrow Science 2000, 290:1779-1782 From Marrow to Brain: Expression of Neuronal Phenotypes in Adult Mice Mezey, E., Chandross, K.J., Harta, G., Maki, R.A., McKercher, S.R. Science 2000, 290:1775-1779 Brazelton, T.R., Rossi, F.M., Keshet, G.I., Blau, H.M. Nature 2001, 410:701-705 Nat Med 2000, 11: 1229-1234 Stem Cell FAQs Do you need to get one from an egg? Must you sacrifice an Embryo? What is an ES cell? What about adult stem cells or cord blood stem cells Why can’t this work be done in animals? Are “cures” on the horizon? Will this lead to human cloning – human spare parts factories? Are we going to make a Frankenstein? What is a stem cell? A primitive cell which can either self renew (reproduce itself) or give rise to more specialised cell types The stem cell is the ancestor at the top of the family tree of related cell types. One blood stem cell gives rise to red cells, white cells and platelets Stem Cells Vary in their Developmental capacity A multipotent cell can give rise to several types of mature cell A pluripotent cell can give rise to all types of adult tissue cells plus extraembryonic tissue: cells which support embryonic development A totipotent cell can give rise to a new individual given appropriate maternal support The Fertilized Egg The “Ultimate” Stem Cell – the Newly Fertilized Egg (one Cell) will give rise to all the cells and tissues of the adult animal.
    [Show full text]
  • Establishment of Bovine Expanded Potential Stem Cells
    Establishment of bovine expanded potential stem cells Lixia Zhaoa,b,c,1, Xuefei Gaod,e,f,1, Yuxuan Zhengg,1, Zixin Wangc, Gaoping Zhaoc, Jie Reng, Jia Zhanga,b, Jian Wuf, Baojiang Wua,b,c, Yanglin Chena,b, Wei Sunb,c, Yunxia Lib,c, Jie Suc,h, Yulin Dingi, Yuan Gaoc, Moning Liuh, Xiaochun Baid,j, Liangzhong Sunk, Guifang Caoh, Fuchou Tangg,l,m, Siqin Baoa,b, Pentao Liuf,n,2, and Xihe Lia,b,c,2 aThe State Key Laboratory of Reproductive Regulation and Breeding of Grassland Livestock, Inner Mongolia University, 010070 Hohhot, China; bResearch Center for Animal Genetic Resources of Mongolia Plateau, College of Life Sciences, Inner Mongolia University, 010070 Hohhot, China; cInner Mongolia Saikexing Institute of Breeding and Reproductive Biotechnology in Domestic Animal, 011517 Hohhot, China; dAcademy of Orthopedics, Guangdong Province, Department of Orthopedic Surgery, The Third Affiliated Hospital of Southern Medical University, 510630 Guangzhou, China; eDepartment of Physiology, School of Basic Medical Sciences, Southern Medical University, 510515 Guangzhou, China; fSchool of Biomedical Science, Stem Cell and Regenerative Consortium, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 999077 Hong Kong; gBeijing Advanced Innovation Center for Genomics, College of Life Sciences, Peking University, 100871 Beijing, China; hCollege of Veterinary Medicine, Key Laboratory of Basic Veterinary Medicine, Inner Mongolia Agricultural University, 010018 Hohhot, China; iCollege of Veterinary Medicine, Key Laboratory of Clinical Diagnosis and
    [Show full text]
  • On Embryonic Stem Cell Research
    On Embryonic Stem Cell Research A Statement of the United States Conference of Catholic Bishops Stem cell research has captured the imagination of many in our society. Stem cells are relatively unspecialized cells that, when they divide, On can replicate themselves and also produce a variety of more specialized cells. Scientists hope these biologi- cal building blocks can be directed to produce many Embryonic types of cells to repair the human body, cure disease, and alleviate suffering. Stem cells from adult tissues, umbilical cord blood, and placenta (often loosely called “adult stem cells”) can be obtained without harm to the Stem Cell donor and without any ethical problem, and these have already demonstrated great medical promise. But some scientists are most intrigued by stem cells obtained by destroying an embryonic human being in the first week Research or so of development. Harvesting these “embryonic stem cells” involves the deliberate killing of innocent human beings, a gravely immoral act. Yet some try to justify it by appealing to a hoped-for future benefit to others. The Imperative to Respect Human Life The Catholic Church “appreciates and encourages the progress of the biomedical sciences which open up unprecedented therapeutic prospects” (Pope Benedict XVI, Address of January 31, 2008). At the same time, it affirms that true service to humanity begins with respect for each and every human life. Because life is our first and most basic gift from an infinitely loving God, it deserves our utmost respect and protection. Direct attacks on innocent human life are always gravely wrong. Yet some researchers, ethi- cists, and policy makers claim that we may directly kill innocent embryonic human beings as if they were mere objects of research—and even that we should make taxpayers complicit in such killing through use of public funds.
    [Show full text]
  • Critical Role for P53 in Regulating the Cell Cycle of Ground State Embryonic Stem Cells
    bioRxiv preprint doi: https://doi.org/10.1101/674960; this version posted June 18, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Critical role for P53 in regulating the cell cycle of ground state embryonic stem cells Menno ter Huurne1,2,#, Tianran Peng1,#, Guoqiang Yi1, Guido van Mierlo1, Hendrik Marks1 & Hendrik G. Stunnenberg1,3,* 1Department of Molecular Biology, Faculty of Science, Radboud University, 6525GA Nijmegen, the Netherlands. 2Present address: Murdoch Children’s Research Institute, Royal Children’s Hospital, Flemington Rd, Parkville, VIC 3052, Melbourne, Australia 3Present address: Princess Maxima Centre for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, The Netherlands #These authors contributed equally Corresponding author: Hendrik G. Stunnenberg *e-mail: [email protected] ; [email protected] Abstract Mouse Embryonic Stem Cells (ESCs) grown in serum-supplemented conditions are characterized by an extremely short G1-phase due to the lack of G1-phase control. Concordantly, the G1-phase-specific P53-P21 pathway is compromised in serum ESCs. Here we provide evidence that P53 is activated upon transition of serum ESCs to their pluripotent ground state using serum-free 2i conditions and modulates G1-phase progression. Our data shows that the elongated G1-phase characteristic of ground state ESCs is dependent on P53. RNA-seq and ChIP-seq analyses reveal that P53 directly regulates the expression of the Retinoblastoma (RB) protein and that the hypo-phosphorylated, active RB protein plays a key role in G1-phase control.
    [Show full text]
  • Stem Cell Differentiation Investigation • 1 C L a S S S E S S I O N
    14 Stem Cell Differentiation investigation • 1 c l a s s s e s s i o n Overview BaCKgrOund infOrMatiOn To investigate how embryonic stem cells become specialized Stem cells and precursors cells cells, students draw from a set of colored chips that represent A stem call produces daughter cells that might remain as specific molecular factors that determine the next step of stem cells or begin a pathway of differentiation into one of a specialization. They discuss the paths stem cells take as they variety of specialized cell types. Stem cells are classified into differentiate into specialized cells. three groups, depending on where they are on the pathway toward differentiation. Totipotent stem cells can produce any Key COntent kind of cell in the body, and have an unlimited ability to self- renew. The embryonic cells that form during the first few 1. Stem cells can produce a variety of specialized cells. divisions after an egg is fertilized are totipotent. Pluripotent 2. The process by which stem cells produce specialized stem cells can become almost any type of cell in the body, descendent cells is called differentiation. except the cells of the placenta and certain other uterine tis- sues. Totipotent stem cells become pluripotent after three or Materials and advanCe PreParatiOn four divisions. Multipotent stem cells produce only certain For the teacher types of cells. For example, one line of multipotent stem cells Transparency 14.1, “The Organization of Multicellular gives rise to all the blood cells, including red and white blood Organisms” cells. Adult stem cells are multipotent.
    [Show full text]
  • Brain Organoids: Advances, Applications and Challenges Xuyu Qian1,2, Hongjun Song1,3,4,5 and Guo-Li Ming1,3,4,6,*
    © 2019. Published by The Company of Biologists Ltd | Development (2019) 146, dev166074. doi:10.1242/dev.166074 REVIEW Brain organoids: advances, applications and challenges Xuyu Qian1,2, Hongjun Song1,3,4,5 and Guo-li Ming1,3,4,6,* ABSTRACT human brain not only at the cellular level, but also in terms of Brain organoids are self-assembled three-dimensional aggregates general tissue structure and developmental trajectory, therefore generated from pluripotent stem cells with cell types and providing a unique opportunity to model human brain development cytoarchitectures that resemble the embryonic human brain. As and function, which are often inaccessible to direct experimentation. such, they have emerged as novel model systems that can be used Combined with recent technological advances, such as patient- to investigate human brain development and disorders. Although derived hiPSCs, genetic engineering, genomic editing, and high- brain organoids mimic many key features of early human brain throughput single cell transcriptomics and epigenetics, brain development at molecular, cellular, structural and functional organoids have revolutionized our toolboxes to investigate levels, some aspects of brain development, such as the formation development, diseases and evolution of the human brain. of distinct cortical neuronal layers, gyrification, and the establishment In this Review, we first introduce recent advances in brain of complex neuronal circuitry, are not fully recapitulated. Here, we organoid technologies, and their applications as model systems summarize recent advances in the development of brain organoid and discovery tools. We then discuss the hurdles that current methodologies and discuss their applications in disease modeling. In methodologies have yet to overcome, and offer feasible suggestions addition, we compare current organoid systems to the embryonic for future steps and objectives that would enable organoid human brain, highlighting features that currently can and cannot be technologies to progress further.
    [Show full text]